FDA Grand Rounds: Some Perspectives on Data Science and Coronaviruses
June 9, 2022
The FDA Grand Rounds is webcast monthly to highlight cutting-edge research underway across the agency and its impact on protecting and advancing public health. Each session features an FDA scientist presenting on a key public health challenge and how FDA is applying science to its regulatory activities.
This lecture will present some perspectives, illustrated with recent COVID-19 experience and examples, on how in silico modelling and data science techniques could strengthen nonclinical (in vitro and animal) models for existing and emerging coronaviral diseases. Four peer-reviewed case studies will be reviewed briefly: 1. Could alignment-free approaches complement traditional phylogenetic analysis of coronavirus variants? 2. Why big data on viral genome sequences are less useful without metadata? 3. Could we predict if certain hosts are likely susceptible to infection by an emerging coronavirus variant? 4. Can AlphaFold2 artificial intelligence predictions of protein structure aid our understanding of viral antigens?
- Supporting pandemic response using genomics and bioinformatics: A case study on the emergent SARS‐CoV‐2 outbreak, https://doi.org/10.1111/tbed.13588
- Interoperable medical data: the missing link for understanding COVID‐19, https://doi.org/10.1111/tbed.13892
- But Mouse, you are not alone: On some severe acute respiratory syndrome coronavirus 2 variants infecting mice, https://doi.org/10.1093/ilar/ilab031
- Highly thermotolerant SARS-CoV-2 vaccine elicits neutralising antibodies against Delta and Omicron in mice, https://doi.org/10.3390/v14040800
- Discuss the research conducted at the FDA
- Explain how FDA science impacts public health
- Examine how coronavirology can benefit from alignment free kmer approach and dimensionality reduction methods.
- Explain the potential of big data on GISAID and other platforms by overcoming metadata barriers.
- Discuss the value of bringing together in silico, in vitro, in vivo and in situ data on coronavirus mutations to predict susceptibility of target hosts.
- Discuss the benefits and current limitations of novel AI tools such as AlphaFold2 in coronaviral protein structure prediction and countermeasure development.
This activity is intended for physicians, pharmacists, nurses, and other scientists within the agency external scientific communities.
Lecture 1 June 9, 2022
|9:00 - 10:00 AM EDT||Some Perspectives on Data Science and Coronaviruses||Seshadri Vasan, , DPhil(Oxon)|
Physicians, pharmacists, nurses, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation via the CE Portal (ceportal.fda.gov). For multi-day activities, participants must attest to their attendance and complete the faculty evaluation each day. Final activity evaluations must be completed within two weeks after the activity - no exceptions.
Attention Pharmacists and Pharmacy Techs: Failure to provide your correct NABP AND Date of Birth information, in the required format, may result in the loss of credit for this activity. NABP profile number should be the 6-7 digit profile number assigned by the CPE Monitor and your birth date should be in the MMDD format (e.g. 0721) Do not provide your pharmacy license number. Please click the "My Account" tab and then navigate to "Edit Contact Information" to verify that your information is correct.
Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit.Physicians and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 8 weeks after the last session of the activity to obtain their CE credit.
- Vasan, Seshadri, , DPhil(Oxon), Honorary Professor, University of York - nothing to disclose
- Dinatale, Miriam, Team Leader, Food and Drug Administration - nothing to disclose
- Pfundt, Tiffany, PharmD, Senior Advisor, HHS/ASPR - nothing to disclose
- Wheelock, Leslie, RN, MS, Director, OSPD, FDA, OC, OCS, OSPD - nothing to disclose
CE Consultation and Accreditation Team
- Bueide, Rachel E., MPhil, Training Specialist, FDA/CDER/OEP/DLOD - nothing to disclose
- Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD - nothing to disclose
Registration is complimentary, therefore refunds are not applicable.
- This warning banner provides privacy and security notices consistent with applicable federal laws, directives, and other federal guidance for accessing this Government system, which includes (1) this computer network, (2) all computers connected to this network, and (3) all devices and storage media attached to this network or to a computer on this network.
- This system is provided for Government-authorized use only.
- Unauthorized or improper use of this system is prohibited and may result in disciplinary action and/or civil and criminal penalties.
- Personal use of social media and networking sites on this system is limited as to not interfere with official work duties and is subject to monitoring.
- By using this system, you understand and consent to the following:
- The Government may monitor, record, and audit your system usage, including usage of personal devices and email systems for official duties or to conduct HHS business. Therefore, you have no reasonable expectation of privacy regarding any communication or data transiting or stored on this system. At any time, and for any lawful Government purpose, the government may monitor, intercept, and search and seize any communication or data transiting or stored on this system.
- Any communication or data transiting or stored on this system may be disclosed or used for any lawful Government purpose.